Axios: AI’s medical promises have become part of the data center debate

Axios: AI’s medical promises have become part of the data center debate

An Axios article explains why medical projects from leading AI companies have become part of the debate over who benefits from new infrastructure and who bears its costs.

On August 31, Axios published an analysis linking medical projects at major AI companies to the debate over data centers, the server facilities used to run and train models. The article presents the treatment of disease as a promise of public benefit amid concerns about land, electricity, computing costs, and the risk that models could be used for harmful biological purposes.

Brookings, citing Data Center Watch, reports that local opposition blocked or delayed 75 data center projects worth $130 billion during the first three months of 2026.

On August 15, Dario Amodei, CEO of the AI company Anthropic, linked public trust in AI to tangible progress in treating cancer. In his original post, he wrote that Anthropic was rapidly expanding its work in biology and medicine and hoped to see the first signs of results in the coming months. Axios places this statement alongside programs at other companies and the broader question of what benefits the growing computing infrastructure will provide.

Anthropic is expanding its work in biology and medicine. NVIDIA and the pharmaceutical company Eli Lilly are building a drug discovery laboratory together. Isomorphic Labs is applying AI to the discovery of new drugs.

Lloyd Price, a partner at the digital health transactions consultancy Nelson Advisors, proposes a test for assessing such promises:

“The question I hear most often is this: where is the contribution or breakthrough that directly led to the development of a drug? Drug development is a team effort, and AI is only one participant.”